Gain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $20,740.00 in Stock

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Eric I. Richman acquired 17,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were bought at an average cost of $1.22 per share, for a total transaction of $20,740.00. Following the transaction, the director now directly owns 289,629 shares in the company, valued at $353,347.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Gain Therapeutics Stock Performance

Gain Therapeutics stock traded down $0.16 during mid-day trading on Monday, reaching $1.12. The company’s stock had a trading volume of 612,586 shares, compared to its average volume of 204,152. Gain Therapeutics, Inc. has a 12-month low of $1.11 and a 12-month high of $5.33. The company has a market capitalization of $20.22 million, a P/E ratio of -0.76 and a beta of 0.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.77 and a current ratio of 2.77. The firm’s fifty day moving average price is $2.32 and its two-hundred day moving average price is $3.29.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. Sell-side analysts predict that Gain Therapeutics, Inc. will post -1.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GANX has been the topic of several recent research reports. Chardan Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research report on Wednesday, March 27th. Oppenheimer reissued an “outperform” rating and set a $9.00 target price on shares of Gain Therapeutics in a research report on Tuesday, April 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Gain Therapeutics in a research report on Tuesday, May 28th.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.